Abstract
Flavone acetic acid (FAA) is a compound with proven activity against various transplantable colon cancers in mice. In this study it was evaluated against primary colon tumours, chemically induced by methylazoxymethanol in outbred CF1 mice. FAA was given i.v. at doses of 70 or 100 or 150 mg kg-1 every 7 days for 6 weeks. Only 4 out of 60 FAA treated mice died of toxicity. FAA reduced tumour number and tumour burden compared to control mice (P <0.05 at least), with no apparent dose-response relationship. Anti-tumour activity of FAA was comparable to that of 5-fluorouracil (5-FU) used as standard. Moreover, FAA was more effective that 5-FU against large tumours. FAA levels in plasma and different tissues (including colonic neoplastic lesions) after a single i.v. dose of 150 mg kg-1 were investigated. Tumour FAA levels appear insufficient to be responsible for the antitumour activity based only on a direct FAA cytotoxic effect. The results confirm clinical interest in FAA and suggest that mechanisms other than direct cytotoxicity may be involved in its activity.
| Original language | English |
|---|---|
| Pages (from-to) | 144-146 |
| Number of pages | 3 |
| Journal | British Journal of Cancer |
| Volume | 58 |
| Issue number | 2 |
| Publication status | Published - 1988 |
Fingerprint
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Response of chemically induced primary colon tumours of the mouse to flavone acetic acid (NSC 347 512). / Pratesi, G.; Manzotti, C.; Damia, G.; D'Incalci, M.
In: British Journal of Cancer, Vol. 58, No. 2, 1988, p. 144-146.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Response of chemically induced primary colon tumours of the mouse to flavone acetic acid (NSC 347 512)
AU - Pratesi, G.
AU - Manzotti, C.
AU - Damia, G.
AU - D'Incalci, M.
PY - 1988
Y1 - 1988
N2 - Flavone acetic acid (FAA) is a compound with proven activity against various transplantable colon cancers in mice. In this study it was evaluated against primary colon tumours, chemically induced by methylazoxymethanol in outbred CF1 mice. FAA was given i.v. at doses of 70 or 100 or 150 mg kg-1 every 7 days for 6 weeks. Only 4 out of 60 FAA treated mice died of toxicity. FAA reduced tumour number and tumour burden compared to control mice (P <0.05 at least), with no apparent dose-response relationship. Anti-tumour activity of FAA was comparable to that of 5-fluorouracil (5-FU) used as standard. Moreover, FAA was more effective that 5-FU against large tumours. FAA levels in plasma and different tissues (including colonic neoplastic lesions) after a single i.v. dose of 150 mg kg-1 were investigated. Tumour FAA levels appear insufficient to be responsible for the antitumour activity based only on a direct FAA cytotoxic effect. The results confirm clinical interest in FAA and suggest that mechanisms other than direct cytotoxicity may be involved in its activity.
AB - Flavone acetic acid (FAA) is a compound with proven activity against various transplantable colon cancers in mice. In this study it was evaluated against primary colon tumours, chemically induced by methylazoxymethanol in outbred CF1 mice. FAA was given i.v. at doses of 70 or 100 or 150 mg kg-1 every 7 days for 6 weeks. Only 4 out of 60 FAA treated mice died of toxicity. FAA reduced tumour number and tumour burden compared to control mice (P <0.05 at least), with no apparent dose-response relationship. Anti-tumour activity of FAA was comparable to that of 5-fluorouracil (5-FU) used as standard. Moreover, FAA was more effective that 5-FU against large tumours. FAA levels in plasma and different tissues (including colonic neoplastic lesions) after a single i.v. dose of 150 mg kg-1 were investigated. Tumour FAA levels appear insufficient to be responsible for the antitumour activity based only on a direct FAA cytotoxic effect. The results confirm clinical interest in FAA and suggest that mechanisms other than direct cytotoxicity may be involved in its activity.
UR - http://www.scopus.com/inward/record.url?scp=0023752866&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023752866&partnerID=8YFLogxK
M3 - Article
C2 - 3166904
AN - SCOPUS:0023752866
VL - 58
SP - 144
EP - 146
JO - British Journal of Cancer
JF - British Journal of Cancer
SN - 0007-0920
IS - 2
ER -